Pfizer Inc. has issued a supplement to its proxy statement for the upcoming 2024 Annual Meeting of Shareholders scheduled for April 25, 2024. The supplement, dated March 28, 2024, informs shareholders of the withdrawal of Item 7 – Amend Director Resignation Processes, which will no longer be presented or voted upon at the meeting. Despite the withdrawal of Item 7, Pfizer has confirmed that the previously distributed proxy cards and voting instruction forms remain valid. Shareholders who have already submitted their votes do not need to take any further action unless they wish to change their vote. The supplement emphasizes that all other agenda items are unaffected and votes will be cast accordingly for matters properly brought before the Annual Meeting. Shareholders who have not yet voted are instructed to disregard Item 7 when completing their proxy cards or voting instruction forms.

Pfizer Inc. has issued a supplement to its proxy statement for the upcoming 2024 Annual Meeting of Shareholders scheduled for April 25, 2024. The supplement, dated March 28, 2024, informs shareholders of the withdrawal of Item 7 – Amend Director Resignation Processes, which will no longer be presented or voted upon at the meeting. Despite the withdrawal of Item 7, Pfizer has confirmed that the previously distributed proxy cards and voting instruction forms remain valid. Shareholders who have already submitted their votes do not need to take any further action unless they wish to change their vote. The supplement emphasizes that all other agenda items are unaffected and votes will be cast accordingly for matters properly brought before the Annual Meeting. Shareholders who have not yet voted are instructed to disregard Item 7 when completing their proxy cards or voting instruction forms.